Abstract：
OBJECTIVE: Visual acuity (VA) and structural biomarker assessment before and 24-months after early detection and routine treatment of second-eye involvement with neovascular age-related macular degeneration (nAMD) and additional comparison with the first eye affected.
METHODS: Prospective, 22-center observational study of participants with unilateral nAMD in the Early Detection of Neovascular AMD (EDNA) study, coenrolled into the Observing Fibrosis, Macular Atrophy and Subretinal Highly Reflective Material, Before and After Intervention with anti-VEGF Treatment (FASBAT) study for an additional 2-year follow-up.
METHODS: Older adults (> 50 years) with new onset nAMD in the first eye.
METHODS: Assessment of both eyes with OCT, color fundus photography (CFP), clinic-measured VA, and quality of life (QoL).
METHODS: Prevalence of atrophy, subretinal hyperreflective material (SHRM), intraretinal fluid (IRF), subretinal fluid (SRF), and changes in VA over the study duration in both the first and second eyes affected with nAMD. Composite QoL scores over time.
RESULTS: Of 431 participants recruited to the FASBAT study, the second eye converted to nAMD in 100 participants at a mean of 18.9 months. Visual acuity was 18 letters better at the time of early diagnosis in the second eye compared with conventional diagnosis in the first eye (72.9 vs. 55.6 letters). Visual acuity remained better in the second eye 24.9 months postconversion, at 69.5 letters compared with 59.7 letters at a similar matched time point in the first eye (18.9 months). A greater proportion of participants had vision > 70 letters in the second eye versus the first eye, 24.9 months postconversion (61 vs. 35). Prevalence of SHRM and IRF was lower in the second eye compared with the first eye 24.9 months postconversion. However, SRF prevalence was greater in the second eye 24.9 months postconversion. The development and progression of total area of atrophy appears similar in both eyes. Mean composite QoL scores increased over time, with a significant correlation between VA for the second eye only 24.9 months postconversion.
CONCLUSIONS: This study has shown that early detection of exudative AMD in the second eye is associated with reduced prevalence of SHRM and IRF and greater VA, which is significantly correlated with maintained QoL.
BACKGROUND: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
METHODS: Prospective, 22-center observational study of participants with unilateral nAMD in the Early Detection of Neovascular AMD (EDNA) study, coenrolled into the Observing Fibrosis, Macular Atrophy and Subretinal Highly Reflective Material, Before and After Intervention with anti-VEGF Treatment (FASBAT) study for an additional 2-year follow-up.
METHODS: Older adults (> 50 years) with new onset nAMD in the first eye.
METHODS: Assessment of both eyes with OCT, color fundus photography (CFP), clinic-measured VA, and quality of life (QoL).
METHODS: Prevalence of atrophy, subretinal hyperreflective material (SHRM), intraretinal fluid (IRF), subretinal fluid (SRF), and changes in VA over the study duration in both the first and second eyes affected with nAMD. Composite QoL scores over time.
RESULTS: Of 431 participants recruited to the FASBAT study, the second eye converted to nAMD in 100 participants at a mean of 18.9 months. Visual acuity was 18 letters better at the time of early diagnosis in the second eye compared with conventional diagnosis in the first eye (72.9 vs. 55.6 letters). Visual acuity remained better in the second eye 24.9 months postconversion, at 69.5 letters compared with 59.7 letters at a similar matched time point in the first eye (18.9 months). A greater proportion of participants had vision > 70 letters in the second eye versus the first eye, 24.9 months postconversion (61 vs. 35). Prevalence of SHRM and IRF was lower in the second eye compared with the first eye 24.9 months postconversion. However, SRF prevalence was greater in the second eye 24.9 months postconversion. The development and progression of total area of atrophy appears similar in both eyes. Mean composite QoL scores increased over time, with a significant correlation between VA for the second eye only 24.9 months postconversion.
CONCLUSIONS: This study has shown that early detection of exudative AMD in the second eye is associated with reduced prevalence of SHRM and IRF and greater VA, which is significantly correlated with maintained QoL.
BACKGROUND: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
摘要：
目的：在早期发现和常规治疗第二只眼受累新生血管性年龄相关性黄斑变性（nAMD）之前和之后24个月进行视觉敏锐度（VA）和结构生物标志物评估，并与第一只眼进行比较受影响。
方法：前瞻性，在新生血管性AMD早期检测（EDNA）研究中对单侧nAMD参与者进行的22个中心观察性研究，共同参与观察纤维化，黄斑萎缩和视网膜下高反射材料，在抗VEGF治疗（FASBAT）研究之前和之后进行额外的2年随访。
方法：老年人（>50岁），第1眼出现新的nAMD。
方法：使用光学相干断层扫描（OCT）评估双眼，彩色眼底照相（CFP），临床测量的视力（VA）和生活质量（QoL）。
方法：萎缩的患病率，视网膜下高反射材料（SHRM），香烟液体(IRF),受nAMD影响的第一和第二只眼的视网膜下液（SRF）和VA在研究期间的变化。随着时间的推移，综合QoL得分。
结果：在FASBAT研究招募的431名参与者中，100名参与者的第二只眼睛在平均18.9个月时转变为nAMD.与第一只眼睛的常规诊断相比，第二只眼睛的早期诊断时VA好18个字母（72.9对55.6个字母）。第二眼转换后24.9个月，与在相似的匹配时间点相比,第一只眼睛的VA为69.5个字母(59.7个字母;18.9个月)。与第一只眼睛相比，第二只眼睛的视力>70个字母的参与者比例更高，转换后24.9个月（61比38）。在转换为nAMD后24.9个月，第二只眼的SHRM和IRF患病率低于第一只眼。然而,转换后24.9个月，第二只眼的SRF患病率更高。双眼萎缩总面积的发展和进展相似。平均复合QoL得分随着时间的推移而增加，转换后仅24.9个月，第二只眼的VA之间存在显着相关性。
结论：这项研究表明，在第二只眼早期发现渗出性AMD与SHRM和IRF患病率降低和视力提高相关，这与维持生活质量显著相关。
方法：前瞻性，在新生血管性AMD早期检测（EDNA）研究中对单侧nAMD参与者进行的22个中心观察性研究，共同参与观察纤维化，黄斑萎缩和视网膜下高反射材料，在抗VEGF治疗（FASBAT）研究之前和之后进行额外的2年随访。
方法：老年人（>50岁），第1眼出现新的nAMD。
方法：使用光学相干断层扫描（OCT）评估双眼，彩色眼底照相（CFP），临床测量的视力（VA）和生活质量（QoL）。
方法：萎缩的患病率，视网膜下高反射材料（SHRM），香烟液体(IRF),受nAMD影响的第一和第二只眼的视网膜下液（SRF）和VA在研究期间的变化。随着时间的推移，综合QoL得分。
结果：在FASBAT研究招募的431名参与者中，100名参与者的第二只眼睛在平均18.9个月时转变为nAMD.与第一只眼睛的常规诊断相比，第二只眼睛的早期诊断时VA好18个字母（72.9对55.6个字母）。第二眼转换后24.9个月，与在相似的匹配时间点相比,第一只眼睛的VA为69.5个字母(59.7个字母;18.9个月)。与第一只眼睛相比，第二只眼睛的视力>70个字母的参与者比例更高，转换后24.9个月（61比38）。在转换为nAMD后24.9个月，第二只眼的SHRM和IRF患病率低于第一只眼。然而,转换后24.9个月，第二只眼的SRF患病率更高。双眼萎缩总面积的发展和进展相似。平均复合QoL得分随着时间的推移而增加，转换后仅24.9个月，第二只眼的VA之间存在显着相关性。
结论：这项研究表明，在第二只眼早期发现渗出性AMD与SHRM和IRF患病率降低和视力提高相关，这与维持生活质量显著相关。
